Clinical and biologic characteristics of patients
. | Stage A . | Stage B . | Stage C . | Stages B+C . | Stages A+B+C . |
|---|---|---|---|---|---|
| No. of patients | 87 | 29 | 11 | 40 | 127 |
| Age, y* | 63.0 | 58.0 | 59.0 | 58.5 | 61.0 |
| Male sex, no. (%) | 51 (59) | 24 (83) | 5 (45) | 29 (72) | 80 (63) |
| Lymphocyte count, × 109/L* | 15.2 | 37.2 | 151.8 | 45.0 | 19.0 |
| Hemoglobin level, g/dL* | 14.1 | 13.4 | 7.2 | 13.0 | 13.8 |
| Platelet count, × 109/L* | 212.5 | 160.0 | 187.5 | 172.0 | 198.0 |
| Lymphocyte doubling time, no (%) | |||||
| More than 12 mo | 64 (84) | NA | NA | NA | NA |
| Less than 12 mo | 12 (16) | NA | NA | NA | NA |
| IGVH genes, no (%) | |||||
| UM | 27 (31) | 17 (59) | 9 (82) | 26 (65) | 53 (42) |
| MT | 60 (69) | 12 (41) | 2 (18) | 14 (35) | 74 (58) |
| ZAP-70, no (%) | |||||
| Less than 20% | 45 (65) | 7 (30) | 3 (33) | 10 (31) | 55 (54) |
| 20% or greater | 24 (35) | 16 (70) | 6 (67) | 22 (69) | 46 (46) |
| L/A ratio, no (%) | |||||
| Less than 1 | 56 (69) | 13 (46) | 2 (20) | 15 (39) | 71 (60) |
| 1 or greater | 25 (31) | 15 (54) | 8 (80) | 23 (61) | 48 (40) |
| Progression, no (%) | 22 (25) | NA | NA | NA | NA |
| CLL-related death, no (%) | 4 (5) | 10 (34) | 6 (55) | 16 (40) | 20 (18) |
. | Stage A . | Stage B . | Stage C . | Stages B+C . | Stages A+B+C . |
|---|---|---|---|---|---|
| No. of patients | 87 | 29 | 11 | 40 | 127 |
| Age, y* | 63.0 | 58.0 | 59.0 | 58.5 | 61.0 |
| Male sex, no. (%) | 51 (59) | 24 (83) | 5 (45) | 29 (72) | 80 (63) |
| Lymphocyte count, × 109/L* | 15.2 | 37.2 | 151.8 | 45.0 | 19.0 |
| Hemoglobin level, g/dL* | 14.1 | 13.4 | 7.2 | 13.0 | 13.8 |
| Platelet count, × 109/L* | 212.5 | 160.0 | 187.5 | 172.0 | 198.0 |
| Lymphocyte doubling time, no (%) | |||||
| More than 12 mo | 64 (84) | NA | NA | NA | NA |
| Less than 12 mo | 12 (16) | NA | NA | NA | NA |
| IGVH genes, no (%) | |||||
| UM | 27 (31) | 17 (59) | 9 (82) | 26 (65) | 53 (42) |
| MT | 60 (69) | 12 (41) | 2 (18) | 14 (35) | 74 (58) |
| ZAP-70, no (%) | |||||
| Less than 20% | 45 (65) | 7 (30) | 3 (33) | 10 (31) | 55 (54) |
| 20% or greater | 24 (35) | 16 (70) | 6 (67) | 22 (69) | 46 (46) |
| L/A ratio, no (%) | |||||
| Less than 1 | 56 (69) | 13 (46) | 2 (20) | 15 (39) | 71 (60) |
| 1 or greater | 25 (31) | 15 (54) | 8 (80) | 23 (61) | 48 (40) |
| Progression, no (%) | 22 (25) | NA | NA | NA | NA |
| CLL-related death, no (%) | 4 (5) | 10 (34) | 6 (55) | 16 (40) | 20 (18) |
NA indicates not applicable.
Median values